Wilmington Savings Fund Society FSB Has $380,000 Stock Position in Natera, Inc. (NASDAQ:NTRA)

Wilmington Savings Fund Society FSB lessened its holdings in Natera, Inc. (NASDAQ:NTRA) by 20.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,400 shares of the medical research company’s stock after selling 633 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Natera were worth $380,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of NTRA. Blue Trust Inc. grew its position in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares in the last quarter. Versant Capital Management Inc grew its position in Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after buying an additional 166 shares in the last quarter. Covestor Ltd increased its stake in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after acquiring an additional 95 shares during the period. GAMMA Investing LLC raised its holdings in Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 106 shares in the last quarter. Finally, True Wealth Design LLC bought a new stake in shares of Natera during the 3rd quarter valued at $57,000. 99.90% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on NTRA. Craig Hallum raised their price target on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. The Goldman Sachs Group raised their target price on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Leerink Partners upped their price target on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Sanford C. Bernstein lifted their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. Finally, Piper Sandler boosted their price objective on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, November 18th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $165.88.

Natera Stock Down 1.4 %

NASDAQ:NTRA opened at $169.71 on Wednesday. Natera, Inc. has a one year low of $67.33 and a one year high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The company has a market cap of $22.41 billion, a PE ratio of -96.43 and a beta of 1.66. The firm’s 50 day simple moving average is $167.72 and its 200 day simple moving average is $141.94.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Natera’s revenue was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.95) earnings per share. On average, research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Insiders Place Their Bets

In other Natera news, CEO Steven Leonard Chapman sold 4,728 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $146.41, for a total transaction of $692,226.48. Following the completion of the transaction, the chief executive officer now owns 185,034 shares in the company, valued at approximately $27,090,827.94. This trade represents a 2.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gail Boxer Marcus sold 2,212 shares of the company’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $158.53, for a total transaction of $350,668.36. Following the completion of the sale, the director now directly owns 19,386 shares in the company, valued at approximately $3,073,262.58. This represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 312,394 shares of company stock valued at $52,333,520. 7.60% of the stock is currently owned by company insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.